Evaluation Of OsteopontinIn Diabetic Nephropathy In Patients With Type2 Diabetes Mellitus

Background:Diabetic nephropathy is the most common cause of end stage renal disease (ESRD) that is associated with high rates of morbidity and mortality. osteopontin (OPN) is a secreted phosphorylated glycoprotein that mediates diverse biological functions. The study aimed to determine the relation between serum OPN and the progression of diabetic nephropathy in patients with type 2 DM. That may open a door for early prediction of diabetic nephropathy. Methods:This case-control study was conducted in Internal Medicine, Endocrinology Unit and Biochemistry Departments in Zagazig University Hospital. This study was carried out on 96 patients devided into: Group 1: 20 age and sex matched healthy volunteers (control group). Group 2: 38 patients with type 2 DM without nephropathy (DWN group) . Group3:38 patients with type 2 DM with nephropathy(DN group).Serum osteopontin concentrations was measured for all cases .Results:HOMA-IR increased significantly in DN group(8.59 ± 1.34) compared with DWN group(4. 73 ± 0.59) and control group(0.90 ± 0.18). serum osteopontin level( ng/ml) increased significantly in the DN group(258.52 ± 46.93 ng/ml) compared with DWN group(159.12 ± 19.56 ng/ml) and control group (70.90 (± 20.47 ng/ml)(p value =0.000).there a high significant correlation between S. OPN and HOMA-IR .Conclusion: Type 2 diabetic patients with or with out nephropathy increased osteopontin levels than control group. Serum osteopontin may be considered as an early prognostic marker for the risk of nephropathy in patients with type 2 diabetes mellitus.